<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968070</url>
  </required_header>
  <id_info>
    <org_study_id>15181</org_study_id>
    <secondary_id>I7A-MC-EACA</secondary_id>
    <nct_id>NCT01968070</nct_id>
  </id_info>
  <brief_title>A Study of LY3127760 in Healthy Participants</brief_title>
  <official_title>A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of this study are to evaluate the safety and how well the body handles
      single and multiple doses of increasing strength of study drug, LY3127760. This study
      includes three parts. Part 3 may be initiated at sponsor's discretion, based on data from
      Part 2. Participants will only enroll in 1 of the 3 study parts. This study will last
      approximately 7 to 13 weeks, depending on part. Screening must be completed within 28 days
      prior to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline to Study Completion (approximately 7-13 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Single Dose LY3127760</measure>
    <time_frame>Pre-dose up to 144 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Single Dose LY3127760</measure>
    <time_frame>Pre-dose up to 144 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Concentration (tmax) of Single Dose LY3127760</measure>
    <time_frame>Pre-dose up to 144 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC[tau]) of Multiple Doses LY3127760</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Multiple Doses LY3127760</measure>
    <time_frame>Post last dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Concentration (tmax) of Multiple Doses LY3127760</measure>
    <time_frame>Post last dose on Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY3127760 (Single)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Single)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3127760 (Multiple)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Multiple)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib (Multiple)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple oral doses of 400 mg celecoxib administered QD for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3127760</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3127760 (Single)</arm_group_label>
    <arm_group_label>Celecoxib (Multiple)</arm_group_label>
    <arm_group_label>Placebo (Single)</arm_group_label>
    <arm_group_label>LY3127760 (Multiple)</arm_group_label>
    <arm_group_label>Placebo (Multiple)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Celecoxib (Multiple)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3127760 (Single)</arm_group_label>
    <arm_group_label>Celecoxib (Multiple)</arm_group_label>
    <arm_group_label>Placebo (Single)</arm_group_label>
    <arm_group_label>LY3127760 (Multiple)</arm_group_label>
    <arm_group_label>Placebo (Multiple)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females as determined by medical history and physical
             examination

          -  Male participants agree to use a reliable method of birth control during the study and
             3 months following the last dose of the investigational product

          -  Female participants not of child-bearing potential

          -  Have a body mass index of 18.5 to 32 kilograms per square meter (kg/m^2) inclusive

          -  Are normotensive (defined as supine systolic blood pressure (BP) less than 140
             millimeters of mercury [mm Hg] and diastolic BP less than 90 mm Hg) without use of any
             antihypertensives

        Exclusion Criteria:

          -  Have known allergies to LY3127760, related compounds or any components of the
             formulation, celecoxib or sulfonamides, or history of significant atopy. Participants
             with known aspirin allergy or allergic reactions to nonsteroidal anti-inflammatory
             drugs (NSAIDs) should also be excluded

          -  Have any current or prior history of a significant gastrointestinal illness such as
             peptic ulcer disease, gastrointestinal (GI) bleeding, chronic gastritis, inflammatory
             bowel disease or chronic diarrhea

          -  Have evidence of other chronic liver disease, including but not limited to chronic
             alcoholic disease, nonalcoholic steatohepatitis, recent history (within 3 months of
             screening) of acute viral hepatitis or chronic autoimmune hepatitis

          -  Have used any NSAIDs, celecoxib, aspirin or acetaminophen (at doses greater than 1
             gram per day), anticoagulants or antiplatelet agents within 14 days of admission

        Part 2 and Part 3 only

          -  Have 1 plus pretrial pitting edema or 2 plus ankle or pedal edema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

